Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Inclusion Criteria: * Willing and able to comply with the requirements for this study and written informed consent. * Male or female age ≥ 18 years * Diagnosis of untreated non severe aplastic anemia. * Platelet counts \< 50 x 10\^9/L at least 2 times consecutively (time interval ≥ 1 week) Exclusion Criteria: * Receive immunosuppressive therapy more than 4 weeks before enrollment * Treatment with TPO-RA within 1 week before enrollment * Inherited bone marrow failure syndromes * Bone marrow fibrosis grade ≥ 2 * The presence of hemolytic PNH clone * The presence of clonal karyotypic abnormalities (del(20q), +8 and -Y are not included in this category) * Previously treated with TPO-RA ≥ 4 weeks * Previously received immunosuppressive therapy ≥ 12 weeks * Ferritin \> 1000 ng/ml (The increased level of Ferritin led by infection is not included in this category) * Have an allergy to eltrombopag or any other part of this medicine. * History of radiotherapy and chemotherapy for malignant solid tumors * Cytopenia caused by other non-hematologic diseases, including liver cirrhosis, active rheumatic connective tissue disease, and persistence of infectious diseases, etc * Abnormal liver function: ALT or AST \> 3 ULN, or TBil \> 1.5 ULN after treatment. * Abnormal kidney function: Creatinine clearance \< 30 ml/min, or serum creatinine (sCr) \>1.5 ULN * Patients with diabetic nephropathy, neuropathy, or eye disease * Patients with poorly controlled hypertension or cardiac arrhythmia * Patients with congestive heart failure and the NYHA grade ≥ 3 historically or currently, and LVEF \< 45% within 4 weeks before enrollment * History of arteriovenous thrombosis within 1 year before enrollment * Participation in another clinical trial within 4 months before the start of this trial * Pregnant or breast-feeding patients * Patients considered to be ineligible for the study by the investigator for reasons other than the above